Closing Volume Interpretation and Bronchodilators Effect
Information source: University of Milan
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy; COPD
Intervention: Indacaterol maleate (Drug); Tiotropium bromide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University of Milan Official(s) and/or principal investigator(s): Pierachille Santus, MD, PhD, Study Director, Affiliation: Università degli Studi di Milano-Pneumologia Riabilitativa-Fondazione Salvatore Maugeri-MILANO
Summary
- The gold standard measures to evaluate small airways (SAW) "in vivo" is not well
understood
- Two tests are today used to measure SAW but real results concordance is not clear
- These problems have a small evidence
- Data about real effect of bronchodilators on SAW (eg Tiotropium and Indacaterol) has
never been studied
- Only an acute bronchodilators effect, after one hour of drugs inhalation, will be
evaluated
- The time frame of study evaluations per patient will be of three hours: one hour for
basal test; one hour rest after drug administration; one hour for post bronchodilators
test
- All enrolled subjects will be outpatients and will be evaluated after 24 hours of
inhalatory drugs washout
Clinical Details
Official title: Small Airways Evaluation and Peripherical Effect of Two Bronchodilators in Healthy Subjects and Stable COPD Patients
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Closing Volume (CV)Closing Capacity (CC)
Secondary outcome: Effect of Tiotropium or Indacaterol on CV and CC registrationComparison concordance of CV and CC
Detailed description:
Evaluation of small airways both in healthy and Chronic Obstructive Pulmonary Disease
(COPD)subjects still today remains a big problem with implications in diagnostic and
clinical management. The first lung alteration in smokers is the bronchiolitis and
possibility to understand real damage on this anatomical district should be very
interesting. The first point of the study will be the SAW evaluation. The two principal
technics to do this are: Single Breath Test (SBT) and oesophageal balloon (EB). With SBT is
possible to obtain the four expiration phases and so the shift from phase 3 to phase 4
identifying the point called closing capacity (CC). With EB is possible to obtain the lung
static pressure-volume curve and after this to identify the point of closing volume (CV).
The real concordance of CC and CV has never been studied both in healthy and COPD subjects.
The SBT is performed by pneumotachograph matched with a gas analyzer. Patient breath
normally for some seconds, exhales to residual volume (RV) and after that deeply inhales
oxygen (100%) to total lung capacity (TLC), then the patient exhales slowly to RV. This test
will be repeated a minimum of three times.
The evaluation of CV will be performed by EB. The oesophageal balloon is introduced by nose
and located in distal oesophageal tract. By pressure transducer the correct position will be
confirmed. After the investigators will perform the evaluation of lung volume, trans pleural
pressure and flow. These parameters will be registered at tidal volume, during forced
expiration and finally during hyperventilation.
So, after the identification of presence,absence and eventually concordance of CC and CV
should be interesting to evaluate the possible effect on SAW of bronchodilators usually used
in clinical practice. More in detail, the investigators will administered in random order
and after basal evaluation of CV and CC dry powder of indacaterol 300 micrograms (mcg) or
Tiotropium 18 mcg. After one hour of drug administration the investigators will repeat the
maneuver for CC and CV evaluations. In this way, will be evaluated only the acute effect of
the bronchodilators on lung hyperinflation. Each subjects will perform plethysmographic test
too. Bronchodilators will be administered only to the COPD patients.
Eligibility
Minimum age: 20 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Signature of informed consent
- Healthy subjects with age from 20 to 80 yars old and never smokers
- COPD diagnosis
- COPD with age from 50 to 85 years old
- History of COPD at least of noe year
- Respiratory stable conditions at least of one month
- Any basal FEV1 expressed in % of predicted value
- FEV1/Forced Vital Capacity (FVC) less than 70%
- COPD with history of former or active smokers with minimum of 20 pack year
Exclusion Criteria:
- Pregnancy
- FEV1/FVC more than 70%
- Known deficit of alpha 1 antitrypsin
- Subjects submitted to a Lung Volume Reduction Surgery (LVRS)
- Subjects with known positivity to Human Immunodeficiency Virus (HIV)
- Known intolerance to a nasogastric balloon
- Misuse of alcool or drugs
- Absence of compliance in performing respiratory test
Locations and Contacts
Pneumologia Riabilitativa-Fondazione Maugeri-Istituto Scientifico di Milano- IRCCS, Milano 20138, Italy
Additional Information
Starting date: August 2011
Last updated: October 28, 2014
|